Use of biomarkers for detecting ovarian cancer
AssigneesThe Johns Hopkins University, Vermillion, Inc.
InventorsDaniel W. Chan, Zhen Zhang, Eric Fung, Xiao-Ying Meng
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.
Claims36
A method of qualifying ovarian cancer status in a subject comprising:
- (a) measuring at least one biomarker in a sample from the subject, wherein the biomarker is selected from the group consisting of ApoA1, transthyretin ΔN10, IAIH4 fragment, and combinations thereof, and
- (b) correlating the measurement with ovarian cancer status.
(canceled)
(canceled)
8-11. (canceled)
13-24. (canceled)
A method comprising:
- (a) measuring a plurality of biomarkers in a sample from the subject, wherein the biomarkers are selected from the group consisting of ApoA1, transthyretin ΔN10 and IAIH4 fragment.
26-30. (canceled)
A method comprising:
- (a) measuring at least one biomarker in a sample from a subject, wherein the biomarker is selected from the group consisting of transthyretin ΔN10 and IAIH4 fragment and combinations thereof.
34-36. (canceled)
A kit comprising:
- (a) a capture reagent that binds a biomarker selected from ApoA1, transthyretin ΔN10 and IAIH4 fragment and combinations thereof;
- and
- (b) a container comprising at least one of the biomarkers.
38-41. (canceled)
A kit comprising:
- (a) a first capture reagent that binds at least one biomarker selected from ApoA1, transthyretin ΔN10 and IAIH4 fragment and
- (b) a second capture reagent that binds at least one of the biomarkers that is not bound by the first capture reagent.
43-46. (canceled)
A kit comprising:
- (a) a first capture reagent that binds at least one biomarker selected from ApoA1, transthyretin ΔN10 and IAIH4 fragment and
- (b) instructions for using the capture reagent to detect the biomarker.
48-53. (canceled)
A purified peptide of SEQ ID NO:1 (IAIH4 fragment).
56-60. (canceled)
A screening test comprising:
- (a) contacting a kallikrein with a kallikrein substrate and with a test agent and
- (b) determining whether the test agent modulates the activity of the kallikrein.
65-66. (canceled)
A method of qualifying ovarian cancer status in a subject comprising:
- (a) measuring at least one biomarker in a sample from the subject, wherein the biomarker is selected from the group consisting of Markers I through XLVIII and combinations thereof, and
- (b) correlating the measurement with ovarian cancer status.
69-70. (canceled)
73-77. (canceled)
Dependencies are inferred from the claim text.